Anti-fibrotic therapy: Are matrix metalloproteinases friends or foes?

Hepatology Research

Volumn 39, Issue 8, 2009, Pages 748-750

  Yoshiji, Hitoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ANGIOTENSIN II; ANTIFIBROTIC AGENT; BATIMASTAT; COLLAGENASE; CTS 1027; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; SUNITINIB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; CELL PROLIFERATION; CELL STIMULATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG TOLERABILITY; EDITORIAL; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE OVEREXPRESSION; GENE THERAPY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MUSCULOSKELETAL DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STELLATE CELL; TRANSGENE; UPREGULATION;

EID: 68349146327     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00573.x     Document Type: Editorial

References (32)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 (Suppl 1): S38-53.
2. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
3. Okita K, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 24-8.
4. Sakaida I, Hironaka K, Uchida K et al. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 1998; 28: 1247-52.
5. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-22.
6. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997; 29: 43-54.
7. Carter EA, McCarron MJ, Alpert E, Isselbacher KJ. Lysyl oxidase and collagenase in experimental acute and chronic liver injury. Gastroenterology 1982; 82: 526-34.
8. Herbst H, Wege T, Milani S et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150: 1647-59.
9. Takahara T, Furui K, Funaki J et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995; 21: 787-95.
10. Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006; 44: 420-9.
11. Lechuga CG, Hernandez-Nazara ZH, Dominguez Rosales JA et al. TGF-beta1 modulates matrix metalloproteinase-13 expression in hepatic stellate cells by complex mechanisms involving p38MAPK, PI3-kinase, AKT, and p70S6k. Am J Physiol Gastrointest Liver Physiol 2004; 287: G974-87.
12. Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004; 40: 1151-9.
13. Yoshiji H, Kuriyama S, Yoshii J et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
14. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007; 22 (Suppl 1): S93-5.
15. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009; 23: 265-76.
16. Jimenez E, Perez de la Blanca E, Urso L et al. Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells. Biochem Biophys Res Commun 2009; 380: 769-74.
17. Yoshiji H, Noguchi R, Ikenaka Y et al. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem 2007; 14: 2749-54.
18. Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000; 9: 413-18.
19. Yoshiji H, Kuriyama S, Yoshii J et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-54.
20. Tugues S, Fernandez-Varo G, Munoz-Luque J et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-26.
21. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
22. Rygiel KA, Robertson H, Marshall HL etal. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008; 88: 112-23.
23. Kahraman A, Bronk SF, Cazanave S etal. The Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res 2009; 39: 805-813.
24. Wielockx B, Lannoy K, Shapiro SD et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001; 7: 1202-8.
25. Yoshiji H, Kuriyama S, Miyamoto Y et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-54.
26. Murawaki Y, Ikuta Y, Idobe Y et al. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26: 1213-19.
27. Murphy FR, Issa R, Zhou X et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition. Implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069-76.
28. Yoshiji H, Kuriyama S, Yoshii J et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36: 850-60.
29. Parsons CJ, Bradford BU, Pan CQ et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004; 40: 1106-15.
30. Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res 2008; 25: 249-58.
31. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134: 1641-54.
32. Canbay A, Feldstein A, Baskin-Bey E etal. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004; 308: 1191-6.